Published Technical Disclosure Archive

Specialized Zika Virus Vaccines for Niche Environments

Publication ID: 24-11857616_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Zika Virus Vaccines for Niche Environments,” Published Technical Disclosure No. 24-11857616_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857616_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,616.

Summary of the Inventive Concept

The present inventive concept relates to specialized Zika virus vaccines adapted for specific, narrow markets or unique operational environments, such as high-security areas, disaster relief, extreme weather conditions, and areas with limited cold chain infrastructure.

Background and Problem Solved

The original patent disclosed a recombinant measles virus expressing Zika virus prM and E proteins, which, while effective, may not be suitable for all environments. The present inventive concept addresses the limitations of the original patent by providing vaccine compositions and methods tailored to specific, high-stakes situations.

Detailed Description of the Inventive Concept

The new inventive concept comprises four specialized vaccine compositions and methods: (1) a vaccine composition for use in high-security areas, engineered to be resistant to extreme temperatures; (2) a method for disaster relief, administering the vaccine composition to individuals in a disaster-stricken area; (3) a system for extreme weather conditions, comprising a portable vaccine storage unit and a recombinant measles virus expressing Zika virus prM and E proteins; and (4) a Zika virus vaccine for use in areas with limited cold chain infrastructure, engineered to be thermostable.

Novelty and Inventive Step

The new inventive concept's novelty lies in its adaptation of the original patent's recombinant measles virus to specific, high-stakes environments, providing a unique solution for each niche market. The inventive step resides in the combination of the original patent's technology with the new claims' specific requirements, such as thermostability and resistance to extreme temperatures.

Alternative Embodiments and Variations

Other embodiments of the inventive concept could include vaccine compositions and methods adapted for use in areas with high mosquito density, or for use in conjunction with other vaccines or therapies. Additionally, the inventive concept could be modified to accommodate different strains of the Zika virus or other flaviviruses.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the vaccine market, particularly in areas with high-security needs, disaster-prone regions, and developing countries with limited cold chain infrastructure. The target industries include biotechnology, pharmaceuticals, and public health organizations.

CPC Classifications

SectionClassGroup
A A61 A61K39/12
C C07 C07K14/005
C C12 C12N7/00
A A61 A61K2039/5254
A A61 A61K2039/53
C C12 C12N2760/18421
C C12 C12N2760/18423
C C12 C12N2770/24122
C C12 C12N2770/24123
C C12 C12N2770/24134

Field of Art

Virology, vaccine development, recombinant viral vector technologies, with specific focus on flavivirus and measles virus-based vaccine platforms

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with expertise in molecular virology, vaccine engineering, with advanced degrees in microbiology or immunology, familiar with recombinant virus design, protein expression systems, and vaccine adaptation strategies

Obviousness Rationale

A person having ordinary skill would recognize that adapting the source patent's recombinant measles virus expressing Zika virus proteins to specific environmental conditions represents a predictable engineering variation. The core viral vector technology remains consistent, with modifications targeting practical deployment challenges such as temperature stability and operational context. These adaptations represent standard problem-solving approaches in vaccine development that would be apparent to a skilled practitioner.

Obvious Combinations & Variations

Source Patent Element
Recombinant measles virus expressing Zika virus prM and E proteins
PTD Variation
Engineering virus to be temperature-resistant for high-security or disaster relief environments
Obviousness Reasoning
Thermostability is a known design parameter in vaccine development, representing a predictable optimization using standard protein engineering techniques
Source Patent Element
Nucleic acid construct with codon optimization for Macaca
PTD Variation
Extending codon optimization strategies to support vaccine performance in extreme environmental conditions
Obviousness Reasoning
Codon optimization is a routine technique for improving protein expression and stability across different contexts
Source Patent Element
Live-attenuated MV vaccine strains like Schwarz, Zagreb, AIK-C, Moraten
PTD Variation
Applying vaccine strains to specialized deployment scenarios like disaster relief and limited infrastructure regions
Obviousness Reasoning
Selecting appropriate vaccine strains for specific operational contexts is a standard design choice in vaccine development
Source Patent Element
Polynucleotide encoding ZIKV prM and E proteins
PTD Variation
Modifying genetic construct to enhance thermostability and resistance to environmental stress
Obviousness Reasoning
Genetic modifications to improve vaccine stability are predictable extensions of existing viral vector technologies
Source Patent Element
Measles virus as viral vector for protein expression
PTD Variation
Adapting viral vector for use in high mosquito density regions with specific protective requirements
Obviousness Reasoning
Viral vector platform technologies are inherently adaptable for different epidemiological contexts through routine engineering approaches
35 U.S.C. § 103 Summary: Based on US Patent 11857616 and the present published technical disclosure, a person having ordinary skill in the art would find the claimed vaccine adaptations obvious, as they represent predictable engineering variations of an established recombinant measles virus platform for Zika virus protein expression. The disclosed modifications constitute routine problem-solving within the field of vaccine development, utilizing known techniques to address specific operational challenges.

Original Patent Information

Patent NumberUS 11,857,616
TitleRecombinant measles virus expressing zika virus prM and E proteins
Assignee(s)CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Institut Pasteur